Jujjavarapu, Chethan
Suri, Pradeep
Pejaver, Vikas
Friedly, Janna
Gold, Laura S.
Meier, Eric
Cohen, Trevor
Mooney, Sean D.
Heagerty, Patrick J.
Jarvik, Jeffrey G.
Funding for this research was provided by:
National Institutes of Health (U24AT009676)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (UH2AT007766)
National Institute of Nursing Research (5UH3AR06679)
Article History
Received: 30 May 2022
Accepted: 29 December 2022
First Online: 6 January 2023
Declarations
:
: The current analysis used data gathered as part of the LIRE Trial. The Institutional Review Boards (IRBs) at Kaiser Permanente Northern California (KPNC) and University of Washington ceded authority to the Group Health Research Institute (GHRI) IRB, which was the IRB of record for the overall study. The IRBs at Henry Ford Health System (HFHS) and Mayo Clinic retained review of the protocol. Each reviewing IRB approved the trial procedures. All participating IRBs: Kaiser Permanente Northern California Institutional Review Board, Group Health Research Institute Human Subjects Review Office, Henry Ford Health System Institutional Review Board, and Mayo Clinic Institutional Review Board agreed that our study was minimal risk and granted waivers of both informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization. The IRB approval number is 476829. All methods were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
: The authors declare that they have no competing interests.